Sanofi Genzyme

Silver Sponsor

Focus: Neurology - Multiple Sclerosis, Rare Diseases

We have long been known for our expertise in rare diseases, including the class of genetic disorders known as lysosomal storage disorders (LSDs).  LSDs such as Pompe disease are prime examples in how Sanofi Genzyme is committed to patients in neurology through innovations in diagnosis and treatment. 

We have also built a franchise in multiple sclerosis that aims to address the unmet needs of this patient community.  At Sanofi Genzyme Canada, one area of significant unmet medical need where our experts have focused their attention is Multiple Sclerosis (MS). Finding effective treatments for a complex disease like multiple sclerosis is no easy task, but our MS research is spearheaded by top experts employing some of the most advanced and creative scientific problem-solving skills in the industry.

Sanofi Genzyme Canada is pleased to offer LemtradaR, a unique therapy with a novel dosing regimen. Lemtrada further complements Genzyme’s current oral therapy, AubagioR (teriflunomide), a once-a-day oral therapy, both approved by Health Canada for the treatment of Relapse-Remitting Multiple Sclerosis.